These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 21729110)

  • 61. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
    Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
    Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21).
    Kem WR
    Behav Brain Res; 2000 Aug; 113(1-2):169-81. PubMed ID: 10942043
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cognitive improvements in a mouse model with substituted 1,2,3-triazole agonists for nicotinic acetylcholine receptors.
    Arunrungvichian K; Boonyarat C; Fokin VV; Taylor P; Vajragupta O
    ACS Chem Neurosci; 2015 Aug; 6(8):1331-40. PubMed ID: 25978789
    [TBL] [Abstract][Full Text] [Related]  

  • 64. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.
    Pichat P; Bergis OE; Terranova JP; Urani A; Duarte C; Santucci V; Gueudet C; Voltz C; Steinberg R; Stemmelin J; Oury-Donat F; Avenet P; Griebel G; Scatton B
    Neuropsychopharmacology; 2007 Jan; 32(1):17-34. PubMed ID: 16936709
    [TBL] [Abstract][Full Text] [Related]  

  • 65. An allosteric binding site of the α7 nicotinic acetylcholine receptor revealed in a humanized acetylcholine-binding protein.
    Delbart F; Brams M; Gruss F; Noppen S; Peigneur S; Boland S; Chaltin P; Brandao-Neto J; von Delft F; Touw WG; Joosten RP; Liekens S; Tytgat J; Ulens C
    J Biol Chem; 2018 Feb; 293(7):2534-2545. PubMed ID: 29237730
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Physiological concentrations of choline activate native alpha7-containing nicotinic acetylcholine receptors in the presence of PNU-120596 [1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)-urea].
    Gusev AG; Uteshev VV
    J Pharmacol Exp Ther; 2010 Feb; 332(2):588-98. PubMed ID: 19923442
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
    Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
    Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Differential effects of subtype-specific nicotinic acetylcholine receptor agonists on early and late hippocampal LTP.
    Kroker KS; Rast G; Rosenbrock H
    Eur J Pharmacol; 2011 Dec; 671(1-3):26-32. PubMed ID: 21968142
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Selective activation of α7 nicotinic acetylcholine receptors augments hippocampal oscillations.
    Stoiljkovic M; Kelley C; Nagy D; Leventhal L; Hajós M
    Neuropharmacology; 2016 Nov; 110(Pt A):102-108. PubMed ID: 27422408
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Positive modulation of alpha7 nAChR responses in rat hippocampal interneurons to full agonists and the alpha7-selective partial agonists, 4OH-GTS-21 and S 24795.
    López-Hernández GY; Thinschmidt JS; Morain P; Trocme-Thibierge C; Kem WR; Soti F; Papke RL
    Neuropharmacology; 2009 Mar; 56(4):821-30. PubMed ID: 19705574
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Tropisetron and its targets in Alzheimer's disease.
    Hashimoto K
    Expert Opin Ther Targets; 2015 Jan; 19(1):1-5. PubMed ID: 25399811
    [TBL] [Abstract][Full Text] [Related]  

  • 72. α7 nicotinic acetylcholine receptors in Alzheimer's disease: neuroprotective, neurotrophic or both?
    Hernandez CM; Dineley KT
    Curr Drug Targets; 2012 May; 13(5):613-22. PubMed ID: 22300028
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Relationship between the increased cell surface alpha7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists.
    Jonnala RR; Buccafusco JJ
    J Neurosci Res; 2001 Nov; 66(4):565-72. PubMed ID: 11746376
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms.
    Mudo G; Belluardo N; Fuxe K
    J Neural Transm (Vienna); 2007 Jan; 114(1):135-47. PubMed ID: 16906354
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Heteromeric α7β2 Nicotinic Acetylcholine Receptors in the Brain.
    Wu J; Liu Q; Tang P; Mikkelsen JD; Shen J; Whiteaker P; Yakel JL
    Trends Pharmacol Sci; 2016 Jul; 37(7):562-574. PubMed ID: 27179601
    [TBL] [Abstract][Full Text] [Related]  

  • 76. α7 Nicotinic receptor agonists as cognitive treatments: is less (or less often) more?
    Buchanan RW; Schwarcz R
    Biol Psychiatry; 2011 Jan; 69(1):5-6. PubMed ID: 21145443
    [No Abstract]   [Full Text] [Related]  

  • 77. Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists.
    Radek RJ; Kohlhaas KL; Rueter LE; Mohler EG
    Curr Pharm Des; 2010 Jan; 16(3):309-22. PubMed ID: 20109141
    [TBL] [Abstract][Full Text] [Related]  

  • 78. New quinoline derivatives as nicotinic receptor modulators.
    Manetti D; Bellucci C; Dei S; Teodori E; Varani K; Spirova E; Kudryavtsev D; Shelukhina I; Tsetlin V; Romanelli MN
    Eur J Med Chem; 2016 Mar; 110():246-58. PubMed ID: 26840365
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The antinociceptive effects of nicotinic receptors α7-positive allosteric modulators in murine acute and tonic pain models.
    Freitas K; Carroll FI; Damaj MI
    J Pharmacol Exp Ther; 2013 Jan; 344(1):264-75. PubMed ID: 23115222
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Genetic deletion of the adenosine A(2A) receptor prevents nicotine-induced upregulation of α7, but not α4β2* nicotinic acetylcholine receptor binding in the brain.
    Metaxas A; Al-Hasani R; Farshim P; Tubby K; Berwick A; Ledent C; Hourani S; Kitchen I; Bailey A
    Neuropharmacology; 2013 Aug; 71():228-36. PubMed ID: 23583933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.